France’s Cytheris banks $15M for immunotherapy work

Paris-based Cytheris has rounded up $15 million in its fourth venture round, with the money earmarked for new R&D work on the developer's immune modulation program. "This financing provides us with the resources to aggressively advance CYT107 through clinical trials, particularly in the HIV and hepatitis markets," said Michel Morre, the president and CEO of Cytheris. "After demonstrating the quality of IL-7 induced immune reconstitution in most patients treated in our HIV studies,...